Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers

被引:0
|
作者
William B Archey
Kristen A McEachern
Mark Robson
Kenneth Offit
Susan AJ Vaziri
Graham Casey
Åke Borg
Bradley A Arrick
机构
[1] Dartmouth Medical School,Department of Medicine
[2] Dartmouth Medical School,Department of Physiology
[3] Dartmouth Medical School,Department of Biochemistry
[4] Memorial Sloan-Kettering Cancer Center,Departments of Human Genetics and Medicine
[5] Cleveland Clinic Foundation,Department of Cancer Biology
[6] University Hospital Lund,Department of Oncology
来源
Oncogene | 2002年 / 21卷
关键词
BRCA1; estrogen receptor; methylation; breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-α (ERα). Previous investigation suggests that methylation of CpGs within the ERα promoter mediates repression of gene expression in some ERα-negative breast cancers. To determine if methylation of CpGs within the ERα promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ERα gene in 40 ERα-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylation-sensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P<0.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ERα gene in BRCA1-linked breast cancers.
引用
收藏
页码:7034 / 7041
页数:7
相关论文
共 50 条
  • [1] Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers
    Archey, WB
    McEachern, KA
    Robson, M
    Offit, K
    Vaziri, SAJ
    Casey, G
    Borg, Å
    Arrick, BA
    ONCOGENE, 2002, 21 (46) : 7034 - 7041
  • [2] Hypermethylation of estrogen receptor-alpha promoter is associated with BRCA1 methylation in estrogen receptor-negative breast cancers
    Wei, MJ
    Dignam, J
    Fackenthal, J
    Sveen, L
    Hagos, F
    Grushko, T
    Olopade, OI
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S67 - S67
  • [3] Molecular basis for estrogen receptor α deficiency in BRCA1-linked breast cancer
    Hosey, Alison M.
    Gorski, Julia J.
    Murray, Margaret M.
    Quinn, Jennifer E.
    Chung, Wen Y.
    Stewart, Gail E.
    James, Colin R.
    Farragher, Susan M.
    Mulligan, Jude M.
    Scott, Alistair N.
    Dervan, Peter A.
    Johnston, Patrick G.
    Couch, Fergus J.
    Daly, Peter A.
    Kay, Elaine
    McCann, Amanda
    Mullan, Paul B.
    Harkin, D. Paul
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (22) : 1683 - 1694
  • [4] Re:: Molecular basis for estrogen receptor α deficiency in BRCA1-linked breast cancer
    Lusa, Lara
    Peissel, Bernard
    Manoukian, Siranoush
    Marchesi, Edoardo
    Radice, Paolo
    Pierotti, Marco A.
    Gariboldi, Manuela
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (10)
  • [5] NFIB is a potential target for estrogen receptor-negative breast cancers
    Moon, Hyeong-Gon
    Hwang, Ki-Tae
    Kim, Jeong-Ah
    Kim, Hee Sung
    Lee, Min-Joo
    Jung, Eun-Mi
    Ko, Eunyoung
    Han, Wonshik
    Noh, Dong-Young
    MOLECULAR ONCOLOGY, 2011, 5 (06) : 538 - 544
  • [6] GATA3 Is a Marker of Estrogen Receptor-Positive but Not Estrogen Receptor-Negative Breast Cancers
    Piscuoglio, S.
    Wen, Y. H.
    Martelotto, L. G.
    Rocco, E. Guerini
    Akram, M.
    Jungbluth, A. A.
    Brogi, E.
    Weigelt, B.
    Reis-Filho, J. S.
    MODERN PATHOLOGY, 2014, 27 : 76A - 76A
  • [7] Increased wound-response revealed by proteomics of estrogen receptor-negative breast cancers
    Neubauer, H.
    Sotlar, K.
    Wallwiener, D.
    Cahill, M. A.
    Solomayer, E.
    Fehm, T.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S61 - S62
  • [8] GATA3 Is a Marker of Estrogen Receptor-Positive but Not Estrogen Receptor-Negative Breast Cancers
    Piscuoglio, S.
    Wen, Y. H.
    Martelotto, L. G.
    Rocco, E. Guerini
    Akram, M.
    Jungbluth, A. A.
    Brogi, E.
    Weigelt, B.
    Reis-Filho, J. S.
    LABORATORY INVESTIGATION, 2014, 94 : 76A - 76A
  • [9] Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers
    Farhat, Ghada N.
    Cummings, Steven R.
    Chlebowski, Rowan T.
    Parimi, Neeta
    Cauley, Jane A.
    Rohan, Thomas E.
    Huang, Alison J.
    Vitolins, Mara
    Hubbell, F. Allan
    Manson, JoAnn E.
    Cochrane, Barbara B.
    Lane, Dorothy S.
    Lee, Jennifer S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07): : 562 - 570
  • [10] Increased wound-response revealed by proteomics of estrogen receptor-negative breast cancers
    Neubauer, H.
    Clare, S.
    Sotlar, K.
    Wallwiener, D.
    Cahill, M. A.
    Solomayer, E.
    Fehm, T.
    ONKOLOGIE, 2008, 31 : 34 - 35